Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use SYMBRAVO safely and effectively. See full prescribing information for SYMBRAVO.SYMBRAVO (meloxicam and rizatriptan) tablets, for oral useInitial U.S. Approval: 2025
Medication labelWhy this: Advisory · dailymed-prescription
SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use SYMBRAVO should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks. SYMBRAVO is not indicated for the preventive treatment of migraine attacks. SYMBRAVO is not indicated for the treatment of cluster headache.
- generic_name
- meloxicam, rizatriptan
- product_names
- meloxicam, rizatriptan
- ndc
- 81968-020, 81968-020-09, 81968-020-03
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en